Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients.

World journal of gastroenterology - 21 Oct 2012

Orito Etsuro, Fujiwara Kei, Kanie Hiroshi, Ban Tesshin, Yamada Tomonori, Hayashi Katsumi

Abstract excerpt

AIM: To analysis the factors that predict the response to entecavir therapy in chronic hepatitis patients with hepatitis B virus (HBV) genotype C. METHODS: Fifty patients [hepatitis B e antigen (HBeAg)-negative:HBeAg-positive = 26:24] with HBV genotype C, who received naïve entecavir therapy for > 2 years, were analyzed. Patients who showed HBV DNA levels ≥ 3.0 log viral copies/mL after 2 years of entecavir...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Viral

Share to Guanine

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 23112549
DOI: 10.3748/wjg.v18.i39.5570
PMCID: PMC3482643

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients.PMID 23112549Read ↗

Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.Semantic proximity Read ↗

Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B.Semantic proximity Read ↗

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.Semantic proximity Read ↗

[Efficacy and predictors of the virologic response to entecavir therapy in nucleoside-naive patients with chronic hepatitis B].Semantic proximity Read ↗

Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.Semantic proximity Read ↗

Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.Semantic proximity Read ↗

Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response.Semantic proximity Read ↗

An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients.Semantic proximity Read ↗

Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.Semantic proximity Read ↗

Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.Semantic proximity Read ↗

Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study.Semantic proximity Read ↗

Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.